Hey Huggy & All,Thanks for all your posts lately & @Jritch90 a...

Hey Huggy & All,

Thanks for all your posts lately & @Jritch90 a nice reward for you winning a smart watch! But of course just a nice surprise in the big scheme of things we are expecting here.

@huggybear_dk, the science behind ATCOR is not boring, it’s foundational for wearable tech. What you might find interesting & I have mentioned this before, is the paradigm shift in clinical trials, the remote collection of data & that this may now continue on with a global pandemic.

Just an example below & how much better would the data have been if we had smart watch capability for standardised blood pressure measurements approved by the FDA.

This trial was purely on smartphones & really was in regards to QOL on a post market trial for an SGLT2i for cardiorenal disease.

https://www.google.com.au/amp/s/www.docwirenews.com/conference-coverage/aha-2021/chief-hf-heart-failure-symptoms-improved-with-canagliflozin-in-remote-trial/amp/


https://www.medscape.com/viewarticle/963094


There are multiple new drugs approved in this space, including Bayer’s Finerenone. We are still engaged with Bayer on other kidney trials, but this one with Janssen (Johnson & Johnson) demonstrates a need for paradigm shift in clinical trials, particularly post market. We have seen a lot of changes, but now you can see how an FDA approved smart device will benefit in an important way.

This above trial has also demonstrated inclusiveness, & that is a big thing including race, so more were able to participate without affecting daily life (that is a big thing on drug trial recruitment). I keep my eye on this space for a couple of other investments & in the last year, Janssen have been investing in Medical technologies to allow these remote trials to happen. Now we are seeing fruition.

I’m sure CDX are all over this clinical need. Regulatory approvals have been slowed, but are moving again with the FDA. GLTAH